Carbapenem-resistant Klebsiella (CRKP)
Carbapenem-resistant Klebsiella pneumoniae (CRKP) is a WHO/CDC critical-priority pathogen: a leading cause of hospital-acquired pneumonia, bloodstream infections, UTIs, and pyogenic liver abscesses, with mortality in invasive disease often exceeding 40-50% because carbapenemase production (KPC, NDM, OXA-48) leaves few or no reliable antibiotics. The rise of hypervirulent, carbapenem-resistant clones (e.g., ST11, ST258) makes the pipeline gap especially acute. Lytic bacteriophages are well suited here because they self-amplify at the site of infection, kill independently of antibiotic-resistance mechanisms, and frequently target the very capsule and lipopolysaccharide structures that drive K. pneumoniae virulence and immune evasion. As a result, phage selection pressure can simultaneously suppress the bacterium and, when resistance does emerge, push the surviving population toward reduced virulence and restored antibiotic susceptibility.
How phages act here
Mechanism
K. pneumoniae phages are highly strain-specific because most bind the polysaccharide capsule (K-type) or LPS O-antigen as their receptor, so cocktails are assembled to span multiple capsular types and depolymerase activities; many therapeutic phages encode capsule depolymerases that strip the protective exopolysaccharide and help degrade biofilm matrix, improving access on catheters, in abscesses, and in the gut reservoir. A central, repeatedly documented mechanism is an evolutionary trade-off: when CRKP mutates its capsule/LPS receptor (e.g., wzc, lpcA, fabF, lps loci) to escape phages, it loses capsule, becomes less virulent in mouse and zebrafish models, and often regains sensitivity to antibiotics. Phage-antibiotic synergy (PAS) is well established for this target — combining phages with carbapenems, aminoglycosides, colistin, or even otherwise inactive agents (trimethoprim-sulfamethoxazole) suppresses resistant mutants and can resensitize the strain. Engineered approaches are advancing rapidly: rationally designed multi-phage cocktails from curated "PhageBanks" minimize resistance, and host-range engineering plus CRISPR-guided and AI/deep-learning-assisted phage design are being used to broaden coverage against diverse clinical CRKP isolates.
Where it stands
Current evidence
As of 2026 the evidence base is strong preclinically and at the level of personalized/compassionate-use case reports, but there is not yet a completed randomized phase 3 trial proving efficacy specifically for CRKP. Documented human cases include personalized phage therapy for multidrug-resistant K. pneumoniae pulmonary infection (nebulized single phage then a two-phage cocktail with concurrent antibiotics; Shanghai Institute of Phage / Fudan University, 2023) and a cured recurrent extensively drug-resistant K. pneumoniae UTI using a non-active-antibiotic-plus-phage synergy strategy (2020). On the translational front, a 2024 Cell Host & Microbe study built a Klebsiella "PhageBank" and rationally designed cocktails that suppressed gut-resident CRKP and drove loss of virulence factors in mice, and multiple 2024-2025 mechanistic papers (mBio, Int J Antimicrob Agents) confirmed the phage-resistance/virulence-loss/antibiotic-resensitization trade-off in CRKP strains. Clinical infrastructure is maturing: UCSD's IPATH center, the NIAID Antibiotic Resistance Leadership Group, and European centers (Eliava Institute, Belgium's Queen Astrid Military Hospital) run compassionate-use programs, and registered IV phage trials in resistant Gram-negative infections (including Klebsiella) are recruiting, though most registered trials to date have centered on Pseudomonas, Staphylococcus, and cystic fibrosis. Net: real, repeatable human signal exists for CRKP via case reports and registries, with controlled efficacy data still pending.
Evidence confidence: medium
The data
Key studies & trials
- Rotman E, McClure S, Glazier J, Fuerte-Stone J, Foldi J, Erani A, McGann R, Arnold J, Lin H, Valaitis S, Mimee M. Rapid design of bacteriophage cocktails to suppress the burden and virulence of gut-resident carbapenem-resistant Klebsiella pneumoniae. Cell Host & Microbe. 2024;32(11):1988-2003.e8. ↗
- Li J, Yan B, He B, Li L, Zhou X, Wu N, Wang Q, Guo X, Zhu T, Qin J. Development of phage resistance in multidrug-resistant Klebsiella pneumoniae is associated with reduced virulence: a case report of a personalised phage therapy. Clinical Microbiology and Infection. 2023;29(12):1601.e1-1601.e7. ↗
- Bao J, Wu N, Zeng Y, Chen L, Li L, Yang L, et al. Non-active antibiotic and bacteriophage synergism to successfully treat recurrent urinary tract infection caused by extensively drug-resistant Klebsiella pneumoniae. Emerging Microbes & Infections. 2020;9(1):771-774. ↗
- Yu Y, Wang M, Ju L, Li M, Zhao M, Deng H, Rensing C, Yang QE, Zhou S. Phage-mediated virulence loss and antimicrobial susceptibility in carbapenem-resistant Klebsiella pneumoniae. mBio. 2025;16(2):e02957-24. ↗
Who is working on it
Programs & centers
The possibility
Within the next several years, phages could shift from last-resort compassionate use to a standard adjunct for CRKP, with hospitals matching a patient's isolate to a curated PhageBank in hours and pairing the cocktail with antibiotics to corner the bacterium into either death or a disarmed, resensitized state. Capsule-degrading depolymerases and CRISPR- and AI-engineered phages promise broad, pre-validated coverage across the dizzying diversity of Klebsiella capsule types, turning today's bespoke therapy into an off-the-shelf precision tool. If ongoing registered trials confirm what the case reports already hint, phage-antibiotic combinations may meaningfully reverse the grim mortality of pan-resistant Klebsiella sepsis.